Role of Next-Generation Sequencing in Driving Oligonucleotide Synthesis Market Growth
https://www.marketsandmarkets.....com/Market-Reports/o
The global oligonucleotide synthesis market is projected to reach USD 19.7 billion by 2029 from USD 8.8 billion in 2024, at a CAGR of 17.5% during the forecast period. The major factors driving the growth of this market are the increasing adoption of oligonucleotides in therapeutics for the treatment of many neurological and rare diseases, ongoing funding and investments provided by the government and major players for life science and synthetic biology research and growing awareness about alternate therapies for various diseases.
The players operating in the oligonucleotide synthesis market are Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai Lifesciences holdings, Inc. (US), Azenta, Inc. (US), Twist Bioscience Corporation (US) and Genscript Biotech Corporation (US).
